Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

This study is testing a drug called asciminib as a second-line treatment for people with chronic myeloid leukemia (CML) — a type of blood cancer — who have already tried one standard targeted therapy (called a TKI) but it stopped working or caused too many side effects. **You may be eligible if...** - You are 18 or older - You have chronic phase CML confirmed by genetic testing - You have had one prior TKI therapy that failed or was not tolerated - Your overall health status is good enough to handle treatment **You may NOT be eligible if...** - Your leukemia has a specific mutation called T315I - You have significant heart problems (severe heart failure, recent heart attack, dangerous heart rhythms) - You have active HIV, hepatitis B or C - You are pregnant or breastfeeding - You have a history of pancreatitis Talk to your doctor to see if this trial is right for you.